v3.26.1
SCHEDULE OF NUMERATOR AND DENOMINATOR OF BASIC AND DILUTED NET INCOME (LOSS) PER SHARE (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Accounting Policies [Abstract]        
Net income (loss) from continuing operations $ (411,144) $ 500,259 $ (13,457) $ (120,307)
Net income (loss) from discontinued operations (41,720) (2,518,657) 19,196 (5,425,474)
Less: Net loss attributable to noncontrolling interests from continuing operations (4,036) (354) (4,242)
Net income (loss) attributable to Sanara MedTech shareholders $ (452,864) $ (2,014,362) $ 6,093 $ (5,541,539)
Weighted average shares, basic 8,662,671 8,612,986 8,732,849 8,591,663
Dilutive effect of stock options 31,013
Dilutive effect of unvested shares 283,061
Weighted average shares, diluted 8,662,671 8,927,060 8,732,849 8,591,663
Net income (loss) per share, basic:        
Continuing operations $ (0.05) $ 0.06 $ (0.01)
Discontinued operations (0.29) (0.63)
Net income (loss) per share of common stock, basic (0.05) (0.23) (0.64)
Net income (loss) per share, diluted:        
Continuing operations (0.05) 0.05 (0.01)
Discontinued operations (0.28) (0.63)
Net income (loss) per share of common stock, diluted $ (0.05) $ (0.23) $ (0.64)